Collegium Pharmaceutical (COLL) Free Cash Flow (2014 - 2026)

Collegium Pharmaceutical's Free Cash Flow history runs 13 years deep, the most recent figure standing at $56.9 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 4.22% year-over-year to $56.9 million in Q1 2026; TTM through Mar 2026 was $331.3 million, a 67.31% increase from a year earlier, with the FY2025 full-year figure at $329.0 million, up 60.65% from the prior year.
• Free Cash Flow slipped to $56.9 million in Q1 2026 per COLL's latest filing, from $123.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $123.8 million in Q4 2025 and bottomed at -$25.4 million in Q1 2022.
• The 5-year median for Free Cash Flow is $65.4 million (2022), against an average of $58.1 million.
• Across the five-year window, Free Cash Flow plunged 226.22% in 2022 and jumped 891.92% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at $65.4 million in 2022, then grew by 11.91% to $73.2 million in 2023, then advanced by 16.9% to $85.5 million in 2024, then jumped by 44.7% to $123.8 million in 2025, then slumped by 54.03% to $56.9 million in 2026.
• Per Business Quant, the three latest COLL Free Cash Flow figures stand at $56.9 million (Q1 2026), $123.8 million (Q4 2025), and $78.2 million (Q3 2025).